The guardian of the genome
Back Bay Boston
With the TARGETS meeting ending and ESMO soon to be starting up, I wanted to offer up a change of pace completely by highlighting some important new cell therapy research presented at the AACR Tumour Immunology and Immunotherapy meeting in Boston.
The CAR-T cell therapy space has certainly seen a lot of developments this year since we wrote about what was coming down the pike in February and here we are in the fourth quarter and the researchers in this niche continue to execute.
I suspect a lot of folks dismissed the first round of gene editing attempts for various reasons without really thinking deeply about why this might be the case and how the issues can be overcome.
This is not the case for the folks at the top of their game – they don’t give up, they go away and find out why things don’t work as expected, how we can overcome them, and importantly, improve on clinical trial execution…
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
